How is the Halozyme Therapeutics Inc. today?

The Halozyme Therapeutics Inc. today is trading in the green, up by 2.45% at 56.07.

How has Halozyme Therapeutics Inc. performed historically?

The Halozyme Therapeutics Inc. is currently trading up 2.45% on an intraday basis in the past week the index rose 2.81%. The index has been down -5.21% in the past quarter and rose 26.60% in the past year. You can view this in the overview section.

What is Halozyme Therapeutics Inc. Annual Revenue?

Halozyme Therapeutics Inc. Annual Revenue rose 22.44%, in the last year to $1,015.32 M. Its sector's average revenue growth for the last fiscal year was 8.76%.

What is Halozyme Therapeutics Inc. Annual Net Profit?

Halozyme Therapeutics Inc. Annual Net Profit rose 57.71% in the last year to $444.09 M. Its sector's average net profit growth for the last fiscal year was -11.09%.

What is Halozyme Therapeutics Inc. Price to Earning Ratio?

Halozyme Therapeutics Inc. Price to Earning Ratio is 14.23, higher than its sector PE ratio of 4.35.

What is Halozyme Therapeutics Inc. Stock Price?

Halozyme Therapeutics Inc. Stock Price rose 26.6% and underperformed its sector by 28.87% in the past year.

What is Halozyme Therapeutics Inc. Quarterly Revenue?

Halozyme Therapeutics Inc. Quarterly Revenue rose 35.22% YoY to $264.86 M. Its sector's average revenue growth YoY for the quarter was 3.14%.

What is Halozyme Therapeutics Inc. Quarterly Net profit?

Halozyme Therapeutics Inc. Quarterly Net profit rose 53.72% YoY to $118.1 M. Its sector's average net profit growth YoY for the quarter was -212.88%.

What is Halozyme Therapeutics Inc. Debt to Equity Ratio?

Halozyme Therapeutics Inc. Debt to Equity Ratio of 4.14 is higher than 1. This implies that company assets are financed through debt.

What is Halozyme Therapeutics Inc. Return on Equity(ROE)?

Halozyme Therapeutics Inc. Return on Equity(ROE) for the last financial year was 198.42%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

What is Halozyme Therapeutics Inc. Mutual Fund Holding?

Halozyme Therapeutics Inc. Mutual Fund Holding decreased by 1.49% in the last quarter to 82.4.

What is Halozyme Therapeutics Inc. Promoter Share Holding?

Halozyme Therapeutics Inc. Promoter Share Holding increased by 0.01% in the most recent quarter to 0.91%.

What is Halozyme Therapeutics Inc. Interest Coverage Ratio?

Halozyme Therapeutics Inc. Interest Coverage Ratio is 31.79, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

What is Halozyme Therapeutics Inc. Institutional Holding?

Halozyme Therapeutics Inc. Institutional Holding increased by 0.14% in the last quarter to 101.23.

Halozyme Therapeutics Inc. XNAS: HALO

Halozyme Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

Name: Halozyme Therapeutics Inc.: Is Infosys Ltd. worth buying?
Item: Halozyme Therapeutics Inc.
Rating: 3.13995825
Author: Trendlyne DVM scores

Mid-range Performer

about

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

56.07 1.34 (2.45%)

31.47% Gain from 52W Low

2.2M XNAS Volume

XNAS 30 May, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Halozyme Therapeutics Inc. is on 09 Jun 2025 for the purpose of Goldman Sachs 46th Annual Global Healthcare Conference 2025 See details

High Financial Strength

83.3 / 100

Mid Valuation

31.5 / 100

Technically Neutral

53.0 / 100

Mid-range Performer These stocks are with strong quality. Their reasonable financials and technical aspects successfully gather investor's interest. View Similar Embed DVM

1Yr Price target upside is 19%

8 analysts

Halozyme Therapeutics Inc. Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Halozyme Therapeutics Inc. Live Share Price Today, Share Analysis and Chart

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary ...

31.47% Gain from 52W Low

SWOT Analysis

Halozyme Therapeutics Inc. Live Price Chart

Halozyme Therapeutics Inc. FAQ

How is Halozyme Therapeutics Inc. today?

Halozyme Therapeutics Inc. today is trading in the green, and is up by 2.45% at 56.07.

How has Halozyme Therapeutics Inc. performed historically?

Halozyme Therapeutics Inc. is currently trading up 2.45% on an intraday basis. In the past week the stock rose 2.81%. stock has been down -5.21% in the past quarter and rose 26.60% in the past year. You can view this in the overview section.